Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Setanaxib, Genfit's dual NOX1/NOX4 inhibitor, targets oxidative stress in PBC and liver fibrosis — how does it compare to seladelpar and obeticholic acid?
Article | Rapport Zinc-ion batteries are emerging as a post-lithium EV storage chemistry. Explore the 2026 technology landscape: cathodes, electrolytes, anode design, and IP strategy.
Article | Rapport IgA nephropathy treatment is being transformed by povetacicept, iptacopan, and sparsentan. Explore the three-way Phase III competitive landscape and key mechanistic differences.
Article | Rapport Key engineering considerations for deploying AI-powered quality inspection systems in regulated pharmaceutical manufacturing — GMP, validation, computer vision, and more.
Article | Rapport Explore the iron-air battery materials landscape in 2026: key patent databases, research groups, electrode chemistry, and how to conduct a rigorous IP analysis.
Article | Rapport A 2026 technology landscape of fiber reinforced biopolymer composites: patent signals, key innovation clusters, application domains, and strategic IP implications.
Article | Rapport PURPOSE-3 and PURPOSE-4 trial readouts extend lenacapavir PrEP evidence to cisgender men and transgender populations globally. Explore Gilead's patent strategy.
Article | Rapport Pyrolysis vs gasification: explore the key technical differences between these thermochemical pathways for plastic waste valorization in the circular economy.
Article | Rapport Explore the lithium-sulfur battery cathode materials landscape: key technical approaches, research directions, and how to navigate the innovation space with PatSnap Eureka.
Article | Rapport sCO₂ turbine patents accelerate from 2018: recompression cycles hit 49% efficiency, Toshiba and Hanwha file EP patents. Full technology landscape for 2026.
Article | Rapport Explore the key engineering challenges of developing next-generation high-entropy alloy coatings for extreme wear applications — from phase stability to tribological performance.
Article | Rapport Olorofim and ibrexafungerp target new pathways to overcome azole resistance in invasive aspergillosis and candidiasis. Explore the clinical pipeline evidence.
Article | Rapport Explore the 2026 thermal spray wear-resistant coating materials landscape: key material systems, deposition processes, application domains, and how to build a sourced IP analysis.
Article | Rapport Comparing etranacogene dezaparvovec (Hemgenix) and fidanacogene elaparvovec (Beqvez) for hemophilia B: what the clinical trials, IP landscape, and real-world data tell us.
Article | Rapport Zero-defect vs AQL inspection philosophies explained for high-volume precision manufacturing. Understand the strategic trade-offs for quality system design.